Pfizer's 3rd-qtr 2008 profit triples due to Exubera write-off; revenues flat at $12B
Pfizer's third-quarter 2008 profit tripled year-on-year as the comparative period was impacted by costs related to the firm's decision to stop marketing its inhaled insulin Exubera (Marketletter October 29, 2007).
The world's largest R&D-based drugmaker by sales saw net income of $2.28 billion, or $0.34 per share, versus $761.0 million, or $0.11 per share, in the third quarter last year. Adjusted earnings totaled $0.62 per share, beating the $0.60 per share average from a Bloomberg analyst survey.
In composite trading on the morning of October 21, when the results were announced, shares in the New York-based company rose 2.3% to $17.73.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze